Funding

None.

Conflicts of Interest

V.Y.S. is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF), is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Eli Lilly, Genentech, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Target-PharmaSolutions, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin, Alumis, Skin Actives Scientific, and the National Eczema Association. J.L.H. is on the board of directors for the Hidradenitis Suppurativa Foundation and has served as a consultant for AbbVie, Aclaris, Boehringer Ingelheim, Incyte, Novartis, and UCB; as a speaker for AbbVie; and as an investigator for Amgen, Boehringer Ingelheim, and Incyte. S.A., C.B.D., E.M., K.A.T., L.T., J.H., and R.M. have no conflicts to disclose.

Ethics Approval

Not applicable.

Patient Consent to Participate/Publish

Not applicable.

Availability of Data and Material

Available upon request.

Code Availability

Not applicable.

Author Contributions

Conceptualization: S.A., L.T., R.M., K.A.T., J.H., J.L.H., and V.Y.S. Methodology: S.A., E.M., R.M., and V.Y.S. Formal Analysis: S.A., C.D., and E.M. Resources: L.T., K.A.T., J.H., J.L.H., and V.Y.S. Writing- Original Draft: S.A. and C.D. Writing- Review and Editing: C.D. and S.A. Supervision: K.A.T., J.H., J.L.H., and V.Y.S. Project administration: K.A.T., J.H., J.L.H., and V.Y.S. All authors read and approved the final manuscript.